COVID-19 (SARS-CoV-2) Antiviral Agents-Nucleotide Analog

"COVID-19 (SARS-CoV-2) Antiviral Agents-Nucleotide Analog" is a specialized compendial or administrative drug classification rather than a standard stand-alone pharmacological taxonomy

In clinical pharmacology, this grouping refers to nucleotide analog antivirals—most notably remdesivir—specifically developed or authorized to combat SARS-CoV-2 infections These agents function as prodrugs that intracellularly convert into active nucleotide triphosphates, directly inhibiting viral RNA-dependent RNA polymerase (RdRp) to induce delayed RNA chain termination or introduce lethal viral mutagenesis Their therapeutic role is centered entirely on infectious disease management, primarily...

In clinical pharmacology, this grouping refers to nucleotide analog antivirals—most notably remdesivir—specifically developed or authorized to combat SARS-CoV-2 infections These agents function as prodrugs that intracellularly convert into active nucleotide triphosphates, directly inhibiting viral RNA-dependent RNA polymerase (RdRp) to induce delayed RNA chain termination or introduce lethal viral mutagenesis